717.25
+3.80
+(0.53%)
At close: 3:30:00 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
20,199,646
18,155,052
19,360,045
11,920,336
--
Cost of Revenue
11,963,696
11,148,378
12,539,679
8,796,993
--
Gross Profit
8,235,950
7,006,674
6,820,366
3,123,343
--
Operating Expense
4,705,454
3,878,557
4,025,278
1,471,720
46
Operating Income
3,530,496
3,128,117
2,795,088
1,651,623
-46
Net Non Operating Interest Income Expense
-219,464
-141,728
-201,144
-119,530
--
Pretax Income
3,418,225
3,004,919
2,607,748
1,553,804
-46
Tax Provision
925,056
835,899
672,813
331,293
--
Net Income Common Stockholders
2,493,149
2,169,020
1,934,934
1,222,511
-46
Diluted NI Available to Com Stockholders
2,493,149
2,169,020
1,934,934
1,222,511
-46
Basic EPS
27.51
23.93
21.35
13.49
-0.00
Diluted EPS
27.50
23.93
21.35
13.49
-0.00
Basic Average Shares
90,611.82
90,626.01
90,626.01
90,626.01
90,626.01
Diluted Average Shares
90,652.86
90,633.56
90,626.01
90,626.01
90,626.01
Rent Expense Supplemental
--
11,593
39,964
1,151
--
Total Expenses
16,669,150
15,026,935
16,564,957
10,268,713
46
Net Income from Continuing & Discontinued Operation
2,493,149
2,169,020
1,934,934
1,222,511
-46
Normalized Income
2,484,228.74
2,160,192.10
1,934,329.27
1,222,402.42
-46
Interest Income
--
30,419
9,373
57
--
Interest Expense
249,883
172,147
210,517
3,401
--
Net Interest Income
-219,464
-141,728
-201,144
-119,530
--
EBIT
3,668,108
3,177,066
2,818,265
1,557,205
-46
EBITDA
4,500,208
3,909,419
3,443,692
1,978,391
-46
Reconciled Cost of Revenue
11,963,696
11,148,378
12,539,679
8,796,993
--
Reconciled Depreciation
832,100
732,353
625,427
421,186
--
Net Income from Continuing Operation Net Minority Interest
2,493,149
2,169,020
1,934,934
1,222,511
-46
Total Unusual Items Excluding Goodwill
12,230
12,230
815
138
--
Total Unusual Items
12,230
12,230
815
138
--
Normalized EBITDA
4,487,978
3,897,189
3,442,877
1,978,253
-46
Tax Rate for Calcs
0
0
0
0
--
Tax Effect of Unusual Items
3,309.74
3,402.10
210.27
29.42
--
3/31/2021 - 1/30/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INNOVACAP.NS Innova Captab Limited
903.65
+0.68%
NECLIFE.BO Nectar Lifesciences Limited
22.89
+0.48%
SUVENPHAR.NS Suven Pharmaceuticals Limited
1,195.70
+0.92%
WINDLAS.NS Windlas Biotech Limited
1,067.50
-0.21%
LAURUSLABS.NS Laurus Labs Limited
626.90
+0.28%
RPGLIFE.NS RPG Life Sciences Limited
2,185.00
+0.77%
IOLCP.NS IOL Chemicals and Pharmaceuticals Limited
64.18
+1.09%
ASTRAZEN.NS AstraZeneca Pharma India Limited
8,514.50
-4.05%
HIKAL.NS Hikal Limited
432.90
+4.41%
WOCKPHARMA.NS Wockhardt Limited
1,392.40
-0.71%